Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Tesnatilimab in Healthy Japanese and Caucasian Males
NCT03002025Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0142-0002 in Crohn's disease (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability. Started Jan 2017; status: completed.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03002025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002025.